Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 2(1)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03996772Phase 3Completed

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

Role: collaborator

NCT03208400Not ApplicableCompleted

Virtual Reality Exposure in Spider Phobia

Role: lead

NCT01030367Not ApplicableUnknown

Pilot Study of Organic Nitrates on Endothelial Function in CAD Patients

Role: lead

NCT00231712Unknown

Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

Role: lead

NCT00108875Phase 1Unknown

Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

Role: lead

NCT00231686Phase 2Completed

Effects of a 6-Months Physical Conditioning Program in Patients With Cystic Fibrosis

Role: lead

All 6 trials loaded